SAMI PHUYAL: Open Payments
NPI 1760157598 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$300 in 15 payments from 10 companies in 2025. Trend: 2023 $141 · 2024 $47 · 2025 $300
Food & beverage: $300
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| Alkermes, Inc. | 2 | $50 |
| ABBVIE INC. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
| Corium, LLC | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
Products named: CAPLYTA, ARISTADA, REXULTI, VRAYLAR, COBENFY, FANAPT, INVEGA SUSTENNA, Azstarys.
Industry payments across ID — which companies pay providers there.
